Pregabalin
Product Images NDC 50090-7558

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-7558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907558)

Label for Pregabalin 25 mg capsules from A-S Medication Solutions. It includes the NDC 50090-7558-0, lot number 7185-0CV, and storage instructions to keep at 77 degrees Fahrenheit. The package contains 90 capsules and states that each capsule contains 25 mg of pregabalin. Also includes a dosage barcode and distributor information in Libertyville, IL.*

FDA Label Image

Equation (Pregabain Gault Equation)

A formula panel illustrating the calculation for creatinine clearance (CLCr) based on age, weight, serum creatinine levels, and adjustment for female patients. It shows the equation used to estimate renal function, relevant in clinical settings.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four curves represent Pregabalin at 200 mg, 100 mg, 25 mg (each taken three times a day), and placebo. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A line chart comparing the percent of patients improved by percent improvement in pain from baseline for Pregabalin 100 mg three times a day versus placebo. The chart shows two curves, one dashed representing Pregabalin and one dotted for placebo, with the vertical axis as percent of patients improved and the horizontal axis as percent improvement in pain from baseline. Vertical reference lines are present at 30% and 50% improvement marks.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses of 75 mg, 150 mg, 300 mg two times a day, and placebo. The graph includes a legend identifying each line type corresponding to the different doses and placebo.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A graph showing the percent of patients improved by percent improvement in pain from baseline for Pregabalin at doses of 100 mg and 200 mg three times a day, compared to placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percent of patients improved. Three lines depict different groups: solid for Pregabalin 200 mg, dashed for Pregabalin 100 mg, and dotted for placebo.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph titled Pregabalin comparing percent improvement in pain from baseline (x-axis) with percent of patients improved (y-axis). Three lines represent Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The graph shows patient improvement percentage across varying pain improvement thresholds.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart comparing responder rates (%) across different doses of Pregabalin and placebo in two studies labeled Study E1 and Study E3. The horizontal axis shows placebo and various Pregabalin doses with BID and TID dosing regimens. Vertical axis shows responder rate from 0% to 60%. Numbers of subjects (N) are listed below each group. Percentages above each bar indicate responder rates for each dose group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction as median percentage change from baseline on the vertical axis and dose in mg/day on the horizontal axis. It compares seizure reduction for four dosing regimens of Pregabalin labeled as Stukly E1BID, E2BID, E3BID, and E3TID at increasing doses. Significant p-values are noted at various dose points, indicating statistical significance of seizure reduction versus placebo (dose 0).*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline, comparing Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. Multiple dose response curves are displayed with distinct line patterns for each dose and placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The y-axis represents the percentage of subjects, ranging from 0% to 100%, and the x-axis represents time in days. Pregabalin and placebo groups are depicted with solid and dashed lines, respectively.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph showing percent of subjects improved on the y-axis versus percent improved from baseline to week 12 (BOCF) on the x-axis. It compares Pregabalin (solid line) with placebo (dotted line), showing higher improvement percentages with Pregabalin across the range compared to placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved from baseline to week 16 using BOCF (Baseline Observation Carried Forward). The x-axis represents the percent improvement, ranging from greater than 0 to 100%, and the y-axis shows the percent of subjects improved, ranging from 0 to 100%. The graph compares two groups: one treated with Pregabalin (solid line) and the other with placebo (dashed line).*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of Pregabalin, illustrating its molecular arrangement including amine, carboxylic acid groups, and carbon chains as per the active ingredient in the product by A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.